Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)
- Registration Number
- NCT00414206
- Lead Sponsor
- CoMentis
- Brief Summary
This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular ("wet") age-related macular degeneration (NV-AMD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Not specified
- Target Recruitment
- 343
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 0.3% mecamylamine Mecamylamine - Placebo Placebo - 1% mecamylamine Mecamylamine -
- Primary Outcome Measures
Name Time Method Proportion of Subjects Losing Fewer Than 15 ETDRS Letters of Visual Acuity at 48 Weeks Compared to Baseline. Baseline to Week 48
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (41)
Hospital de Olhos de Araraquara
🇧🇷Araraquara, Brazil
Centro Brasileiro de Ciências Visuais
🇧🇷Belo Horizonte, Brazil
Instituto da Visão
🇧🇷Belo Horizonte, Brazil
Centro Brasileiro de Cirurgia dos Olhos
🇧🇷Goiânia, Brazil
Hospital de Clinicas de Porto Alegre
🇧🇷Porto Alegre, Brazil
Hospital Universitário Clementino Fraga Filho
🇧🇷Rio de Janeiro, Brazil
Clínica de Olhos Dr. Suel Abujamra
🇧🇷São Paulo, Brazil
Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo
🇧🇷São Paulo, Brazil
Hospital de Olhos de São Paulo
🇧🇷São Paulo, Brazil
Hospital São Paulo - Setor de Pesquisa Clínica
🇧🇷São Paulo, Brazil
Scroll for more (31 remaining)Hospital de Olhos de Araraquara🇧🇷Araraquara, Brazil